Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) is anticipated to issue its earnings data after the market closes on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $13.11 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Aquestive Therapeutics Stock Performance
Shares of AQST stock opened at $2.65 on Tuesday. The firm has a market cap of $241.62 million, a P/E ratio of -5.89 and a beta of 2.67. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The business’s 50 day moving average price is $3.18 and its 200-day moving average price is $4.16.
Analyst Ratings Changes
AQST has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $11.00.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Stories
- Five stocks we like better than Aquestive Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Capture the Benefits of Dividend Increases
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Options Trading – Understanding Strike Price
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
